Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Ohyashiki, Kazuma ^a   Umezu, Tomohiro ^a   Yoshizawa, Sei Ichiro ^a   Ito, Yoshikazu ^a   Ohyashiki, Michiyo ^a   Kawashima, Hisashi ^a   Tanaka, Masami ^a   Kuroda, Masahiko ^a   Ohyashiki, Junko H ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 92A; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN92 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER RELAPSE; CLINICAL EVALUATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FOLLICULAR LYMPHOMA; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPHANGIOGENESIS; MALE; MICROARRAY ANALYSIS; NONHODGKIN LYMPHOMA; PATIENT MONITORING; SENSITIVITY AND SPECIFICITY; T CELL LYMPHOMA; TREATMENT RESPONSE; TUMOR VASCULARIZATION; AGED; BLOOD; BLOOD ANALYSIS; EVALUATION; GENETICS; METHODOLOGY; MIDDLE AGED; PROGNOSIS; RISK; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CHEMICAL ANALYSIS; DOWN-REGULATION; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MICROARRAY ANALYSIS; MICRORNAS; MIDDLE AGED; PROGNOSIS; RISK; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 79952089256     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016408     Document Type: Article

References (40)

1. Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD, (2008) MicroRNAs: new regulators of immune cell development and function. Nat Immunol 9: 839-845.
2. Bartel DP, (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
3. He L, Hannon GJ, (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531.
4. Esquela-Kerscher A, Slack FJ, (2006) Oncomirs: microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
5. Garzon R, Calin GA, Croce CM, (2009) MicroRNAs in cancers. Annu Rev Med 60: 167-179.
6. Iorio MV, Croce CM, (2009) MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 27: 5848-5856.
7. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, et al. (2004) A microRNA polycistron as a potential human oncogene. Nature 435: 828-833.
8. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, et al. (2008) Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9: 405-414.
9. Ventura A, Young AG, Winslow MM, Winslow MM, Lintault L, et al. (2008) Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132: 875-886.
10. Sander S, Bullinger L, Wirth T, (2009) Repressing the repressor: a new mode of MYC action in lymphomagenesis. Cell Cycle 8: 556-559.
11. Tagawa H, Karube K, Tsuzuki S, Ohshima K, Seto M, (2007) Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development. Cancer Sci 98: 1482-1490.
12. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, et al. (2005) A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 65: 9628-9632.
13. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, et al. (2008) MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A 105: 12885-12890.
14. Takakura S, Mitsutake N, Nakashima M, Namba H, Saenko VA, et al. (2008) Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci 99: 1147-1154.
15. Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N, et al. (2009) MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 113: 396-402.
16. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, et al. (2006) Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nature Genet 38: 1060-1065.
17. Doebele C, Bonauer A, Fischer A, Scholz A, Reiss Y, et al. (2010) Members of the microRNA 17-92 cluster exhibit a cell intrinsic anti-angiogenetic function in endothelia cells. Blood 115: 4944-4950.
18. Boanuer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, et al. (2009) MicroRNA-92a controls angiogenesis and functional recovery of ischemia tissues in mice. Science 324: 1710-1713.
19. Koster A, Raemaekers JM, (2005) Angiogenesis in malignant lymphoma. Curt Opin Oncol 17: 611-616.
20. Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, et al. (2003) Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 102: 638-645.
21. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10513-10518.
22. Gilad S, Meiri E, Yogev Y, Lebanony D, Yerushalmi N, et al. (2008) Serum microRNAs are promising novel biomarkers. PLoS One 3: e3148.
23. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, et al. (2009) Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 3: e3694.
24. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, et al. (2009) The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 112: 55-59.
25. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, et al. (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141: 672-625.
26. Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J, et al. (2009) Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 4: e5532.
27. Shigoka M, Tsuchida A, Matsudo T, Nagakawa Y, Saito H, et al. (2010) Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int 60: 351-357.
28. Lawrie CH, Chi J, Taylor S, Tramonti D, Ballabio E, et al. (2009) Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med 13: 1248-1260.
29. Zhang J, Jima DD, Jacobs C, Fischer R, Gottwein E, et al. (2009) Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood 113: 4586-4594.
30. Navarro A, Beà S, Fernández V, Solé F, Royo C, et al. (2009) MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas. Cancer Res 69: 7071-7078.
31. Nagel S, Venturini L, Przybylski GK, Grabarczyk P, Schmidt CA, et al. (2009) Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia. Leuk Lymphoma 50: 101-108.
32. Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, et al. (2007) Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 109: 4399-4405.
33. Sasaki K, Kohanbash G, Hoji A, Ueda R, McDonald HA, et al. (2010) miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy. J Translat Med 8: 17.
34. Valadi H, Ekstrom K, Bossios A, Sjöstrand M, Lee JJ, et al. (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654-659.
35. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, et al. (2010) Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 285: 17442-17452.
36. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, et al. (2010) Circulating microRNAs in patients with coronary artery disease. Circ Res 107: 677-684.
37. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, et al. (2007) Genetic unmasking of epigenetically silenced microRNA in human cancer cells. Cancer Res 67: 1424-1429.
38. Han L, Witmer PD, Casey E, Valle D, Sukumar S, (2007) DNA methylation regulates microRNA expression. Cancer Biol Ther 6: 1284-1288.
39. Cheson BD, Horning DJ, Coiffier V, Shipp MA, Fisher RI, et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. NCI sponsored international working group. J Clin Oncol 17: 1244-1253.
40. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, et al. (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25: 579-586.